Broadening the phenotypic and molecular spectrum of FINCA syndrome: Biallelic NHLRC2 variants in 15 novel individuals
Henrike L Sczakiel,Max Zhao,Brigitte Wollert-Wulf,Magdalena Danyel,Nadja Ehmke,Corinna Stoltenburg,Nadirah Damseh,Motee Al-Ashhab,Tugce B Balci,Matthew Osmond,Andrea Andrade,Jens Schallner,Joseph Porrmann,Kimberly McDonald,Mingjuan Liao,Henry Oppermann,Konrad Platzer,Nadine Dierksen,Majid Mojarrad,Atieh Eslahi,Behnaz Bakaeean,Daniel G Calame,James R Lupski,Zahra Firoozfar,Seyed Mohammad Seyedhassani,Seyed Ahmad Mohammadi,Najwa Anwaar,Fatima Rahman,Dominik Seelow,Martin Janz,Denise Horn,Reza Maroofian,Felix Boschann
DOI: https://doi.org/10.1038/s41431-023-01382-0
Abstract:FINCA syndrome [MIM: 618278] is an autosomal recessive multisystem disorder characterized by fibrosis, neurodegeneration and cerebral angiomatosis. To date, 13 patients from nine families with biallelic NHLRC2 variants have been published. In all of them, the recurrent missense variant p.(Asp148Tyr) was detected on at least one allele. Common manifestations included lung or muscle fibrosis, respiratory distress, developmental delay, neuromuscular symptoms and seizures often followed by early death due to rapid disease progression.Here, we present 15 individuals from 12 families with an overlapping phenotype associated with nine novel NHLRC2 variants identified by exome analysis. All patients described here presented with moderate to severe global developmental delay and variable disease progression. Seizures, truncal hypotonia and movement disorders were frequently observed. Notably, we also present the first eight cases in which the recurrent p.(Asp148Tyr) variant was not detected in either homozygous or compound heterozygous state.We cloned and expressed all novel and most previously published non-truncating variants in HEK293-cells. From the results of these functional studies, we propose a potential genotype-phenotype correlation, with a greater reduction in protein expression being associated with a more severe phenotype.Taken together, our findings broaden the known phenotypic and molecular spectrum and emphasize that NHLRC2-related disease should be considered in patients presenting with intellectual disability, movement disorders, neuroregression and epilepsy with or without pulmonary involvement.